Abstracts tagged "osteoporosis"

Abstract Number: 0124 • ACR Convergence 2020
Appropriate Timing of Denosumab Dosing and Subsequent Therapy After Discontinuation: An Academic Medical Center Experience
Hugo Raposo¹, Daniel Lindstrom¹ and Jonathan Cheah², ¹University of Massachusetts Medical School, Worcester, MA, ²University of Massachusetts Medical School, Shrewsbury, MA
Background/Purpose: Denosumab, a monoclonal antibody that binds to the receptor activator of nuclear factor kappa-B ligand (RANKL) is a popular choice for osteoporosis therapy. However,…
Abstract Number: 1336 • ACR Convergence 2020
Bone Mineral Density, Trabecular Bone Score and Proximal Femur 3D-DXA Analysis in Psoriatic Diseases
Eric Toussirot¹, Renaud Winzenrieth², Maxime Desmarets³, Daniel Wendling⁴, Francois Aubin⁵ and Gilles Dumoulin⁶, ¹CIC biotherapies, Besançon University Hospital, Besançon, France, ²GALGO medical, Barcelona, Spain, ³INSERM CIC-1431, Besancon, France, ⁴CHU Besançon, department of rheumatology, Besancon, France, ⁵Dermatology, Besancon, France, ⁶Laboratoire de Biochimie Médicale, UF de Biochimie Endocrinienne et Métabolique, Besancon, France
Background/Purpose: current data regarding areal bone mineral density (aBMD) in patients with psoriasis (PsO) or psoriatic arthritis (PsA) are conflicting. Results on Trabecular Bone Score…
Abstract Number: 0107 • ACR Convergence 2020
Effects of Abaloparatide on Modeling and Remodeling Based Bone Formation
David W Dempster¹, Hua Zhou¹, Sudhaker D Rao², Chris Recknor³, Paul D Miller⁴, Benjamin Z Leder⁵, Miriam Annett⁶, Michael S Ominsky⁶ and Bruce H Mitlak⁶, ¹Regional Bone Center, Helen Hayes Hospital, West Haverstraw, NY, West Haverstraw, NY, ²Bone & Mineral Research Laboratory, Henry Ford Health System, Detroit, MI, Detroit, MI, ³United Osteoporosis Centers, Gainesville, GA, Gainesville, GA, ⁴Colorado Center for Bone Research, Lakewood, CO, Lakewood, CO, ⁵Mass General Hospital, Harvard Medical School, Boston, MA, Boston, MA, ⁶Radius Health, Inc., Waltham, MA, Waltham, MA
Background/Purpose: To evaluate abaloparatide-induced changes in the bone formation indices of mineralizing surface (MS), bone formation rate (BFR) and mineral apposition rate (MAR); and to…
Abstract Number: 0125 • ACR Convergence 2020
A Resident-Led Interdisciplinary Quality Improvement Initiative to Increase Osteoporosis Screening in an Urban Clinic
Catherine Teskin¹ and Hiba Sayed², ¹Christiana Care, Wilmington, ²Christiana Care, wilmington, DE
Background/Purpose: Osteoporosis is a major cause of morbidity and mortality in the United States. The USPSTF recommends screening all women age 65 and older or…
Abstract Number: 1337 • ACR Convergence 2020
Relationship of the Pro12Ala Polymorphism of the PPARg Gene with Inflammatory Activity, Osteoporosis and Obesity in Patients with Psoriatic Arthritis
Olga Compán¹, Maria Elisa Acosta², Sonia Pastor², Guadalupe Manzano Canabal², Luis Gomez-Lechon Quiros³, Cristina Hidalgo Calleja⁴, Noelia Cubino², Ricardo Usategui⁵, Rogelio Gonzalez Sarmiento⁵, Olga Martinez Gonzalez⁶, Ana Isabel Turrión², Javier Del Pino-Montes² and Carlos Montilla Morales², ¹Hospital Universitario de Salamanca, ´Salamanca, Spain, ²Hospital Universitario de Salamanca, Salamanca, Spain, ³Complejo Asistencial Universitario de Salamanca, Salamanca, Spain, ⁴Hospital Universitario Salamanca, Salamanca, Spain, ⁵Instituto de Investigación Biomédica de Salamanca, Salamanca, Spain, ⁶Hospital Universitario de Salamanca, Zamora, Spain
Background/Purpose: In the pathogenesis of psoriatic arthritis (PsA), increased inflammatory cytokines lead to increased RANGO-L activity and stimulation of osteoclasts, leading to osteoporosis. This comorbidity,…
Abstract Number: 0108 • ACR Convergence 2020
The Relationship Between Body Fat Percentage and Bone Mineral Density in Rheumatoid Arthritis Patients
Anastasia- Vasiliki Madenidou¹ and Marwan Bukhari², ¹Rheumatology Department, University Hospitals of Morecambe Bay NHS Trust, Barrow-in-Furness, United Kingdom, ²Rheumatology Department, University Hospitals of Morecambe Bay NHS Trust, Lancaster, United Kingdom
Background/Purpose: Currently, Dual-Energy X-ray Absorptiometry (DEXA) scans are used to determine fracture risk by calculating Bone Mineral Density (BMD). It is well established that body…
Abstract Number: 0127 • ACR Convergence 2020
Biochemical Algorithm to Identify Individuals with ALPL Variants Between Subjects with Persistent Hypophosphatasaemia
Carolina Tornero¹, Victoria Navarro-Compán², Jair Antonio Tenorio³, Sara Garcia-Carazo⁴, Antonio Buño⁵, Irene Monjo¹, Chamaida Plasencia⁶, José Manuel Iturzaeta⁵, Pablo Lapunzina⁷, Karen Heath⁷, Alejandro Balsa⁶ and Pilar Aguado⁸, ¹Rheumatology, La Paz University Hospital- IdiPAZ, Madrid, Spain, ²Hospital Universitario La Paz IdiPaz, Madrid, Pais Vasco, Spain, ³Institute of Medical and Molecular Genetics (INGEMM), La Paz University Hospital-IdiPAZ, Madrid, Madrid, Spain, ⁴Rheumatology, La Paz University Hospital-IdiPAZ, Madrid, Melilla, Spain, ⁵Department of Clinical Biochemistry, La Paz University Hospital, Madrid, Madrid, Spain, ⁶Rheumatology, La Paz University Hospital-IdiPAZ, madrid, Spain, ⁷Institute of Medical and Molecular Genetics (INGEMM), La Paz University Hospital, IdiPAZ, Madrid, Madrid, Spain, ⁸Rheumatology, La Paz University Hospital-IdiPAZ, Madrid, Madrid, Spain
Background/Purpose: Studies show a long diagnostic delay in Hypophosphatasia (HPP) and the accessibility for the genetic testing is not always possible. Our previous cross-sectional study…
Abstract Number: 1442 • ACR Convergence 2020
Denosumab versus Oral Bisphosphonate for Osteoporosis in Long-term Glucocorticoid Users: A 12-month Randomized Controlled Trial
Chi Chiu Mok¹, Ling Yin Ho¹ and Kwok Man Ma¹, ¹Tuen Mun Hospital, Hong Kong, China (People's Republic)
Background/Purpose: To compare the efficacy of denosumab (DEN) and oral alendronate (ALN) on spinal bone mineral density (BMD) in long-term glucocorticoid users.Methods: Patients receiving long-term…
Abstract Number: 0109 • ACR Convergence 2020
Glucocorticoid-Induced Osteoporosis: Are We Practicing Prevention?
Eileen Rife¹, Emejuaiwe Nkechinyere² and Jose Leon de la Rocha³, ¹Louisiana State University, Metairie, LA, ²Department of Veterans Affairs, New Orleans, LA, ³Louisiana State University, Auburn, AL
Background/Purpose: Descriptive study designed to assess compliance to evidence-based practice guidelines for the prevention of Glucocorticoid-Induced Osteoporosis (GIOP).Methods: We queried the electronic database of the…
Abstract Number: 0129 • ACR Convergence 2020
Glucocorticoid-Induced Osteoporosis in Patients with Chronic Inflammatory Rheumatic Diseases: A Multivariate Linear Regression Analysis Identifying Factors Affecting Bone Mineral Density
Edgar Wiebe¹, Desiree Freier¹, Dörte Huscher², Sandra Hermann¹, Robert Biesen³ and Frank Buttgereit⁴, ¹Charité University Medicine Berlin, Dep. of Rheumatology and Clinical Immunology, Berlin, Germany, ²Charité University Medicine Berlin, Dep. of Biometry and Clinical Epidemiology, Berlin, Germany, ³Charité University Medicine, Dep. of Rheumatology and Clinical Immunology, Berlin, ⁴Charité University Medicine, Berlin, Germany
Background/Purpose: Rheumatic diseases are associated with increased systemic bone loss and fracture risk related to chronic inflammation, disease-specific, general and demographic risk factors as well…
Abstract Number: 1558 • ACR Convergence 2020
Cinematic Rendering Enables Depiction of Bone Anabolic Effects in Patients Treated with Baricitinib
Sara Bayat¹, David Simon², Louis Schuster², Georg Schett³ and Arnd Kleyer², ¹Department of Internal Medicine 3, Friedrich-Alexander University (FAU) Erlangen-Nuremberg and Universitätsklinikum Erlangen, Erlangen, Germany, ²Department of Internal Medicine 3, Friedrich-Alexander University (FAU) Erlangen-Nuremberg and Universitätsklinikum Erlangen, Erlangen, Bayern, Germany, ³Friedrich-Alexander-Universität Erlangen- Nuremberg, Erlangen, Germany
Background/Purpose: Preclinical studies show that tsDMARDs such as baricitinib may be a therapeutic agent for bone anabolic effects by increasing osteoblast function in inflammatory conditions.[1]…
Abstract Number: 0111 • ACR Convergence 2020
Assessment and Treatment of Glucocorticoid-Induced Osteoporosis in a Rheumatology Clinic
Amanda Stefl¹, Shikha Singla², Jessica Michaud¹, Kama Thomas², Lisa Rein² and Mary Ellen Csuka², ¹Froedtert Hospital, Milwaukee, WI, ²Medical College of Wisconsin, Milwaukee, WI
Background/Purpose: Glucocorticoids (GC) are used as a long-term treatment option for an estimated 1% of the US population. The American College of Rheumatology has maintained…
Abstract Number: 0130 • ACR Convergence 2020
The Prevalence of Osteoporosis in Individuals with Osteoarthritis: A Systematic Review
Timothy Varghese¹, Ali Ahmadi Pirshahid², Dongkeun Kim² and Yueyang Li², ¹Schulich School of Medicine & Dentistry, Richmond Hill, ON, Canada, ²Schulich School of Medicine & Dentistry, London, ON, Canada
Background/Purpose: There is controversy regarding the relationship between osteoarthritis (OA) and osteoporosis (OP). While OA may be associated with increased bone mineral density (BMD) due…
Abstract Number: 1588 • ACR Convergence 2020
A Quality Improvement Project to Improve Bone Densitometry Ordering in Adult Patients on Chronic Glucocorticoids
Katherine Kaufman¹, Philip Chu¹, Mithu Maheswaranathan¹, Andrew Johannemann¹, D Ryan Anderson¹, Isaac Smith¹, Akrithi Udupa¹, Mary Buckley¹, Laura Cannon¹, Rachel Randell¹ and David Leverenz¹, ¹Duke University, DURHAM, NC
Background/Purpose: The 2017 ACR guideline for glucocorticoid-induced osteoporosis (GIOP) recommends DXA testing in patients aged ≥40 years on chronic glucocorticoids. We performed a quality improvement…
Abstract Number: 270 • 2019 ACR/ARP Annual Meeting
Outcomes of a Fracture Liaison Service at an Academic Health Center
Micah Yu¹, Donna Jose ², Parke Hudson ², Christina Downey, MD ³, Wesley Phipatanakul ², Silvana Giannelli ², Kevin Codorniz ⁴ and Karina Torralba ⁵, ¹Loma Linda University Medical Center, loma linda, ²Loma Linda University, Loma Linda, ³Loma Linda University Medical Center, Loma LInda, CA, ⁴[email protected], Loma Linda, ⁵Loma Linda University School of Medicine, Loma Linda, CA
Background/Purpose: Osteoporosis is associated with increased morbidity and mortality. There is a 60% risk of a subsequent fracture for patients who have had one fracture,…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].